Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/7/2025

IV Morphine Conversion from Intrathecal Morphine

Conversion Principles

  • Intrathecal morphine is approximately 100-300 times more potent than IV morphine due to direct spinal cord delivery bypassing systemic circulation, according to the National Comprehensive Cancer Network 1
  • Using a conservative conversion ratio of 1:100 (intrathecal to IV), 52 mcg/day intrathecal morphine equals approximately 5.2 mg/day IV morphine, as recommended by the National Comprehensive Cancer Network 1
  • Using a more aggressive ratio of 1:300, this would equal approximately 15.6 mg/day IV morphine, as suggested by the National Comprehensive Cancer Network 1

Dosing and Titration

  • The National Comprehensive Cancer Network recommends starting with the lower end of the conversion range (approximately 5 mg/day IV morphine) and titrating upward based on pain control 1
  • If pain control is inadequate after 24 hours, increase the total daily dose by 25-50% to achieve adequate analgesia, as advised by the National Comprehensive Cancer Network 1
  • Provide breakthrough doses of 1 mg IV morphine every 15 minutes as needed for inadequate pain control, according to Praxis Medical Insights 2

Safety Considerations

  • Patients previously on intrathecal opioids are opioid-tolerant but may experience withdrawal if under-dosed, warns the National Comprehensive Cancer Network 1
  • The wide conversion ratio range (1:100 to 1:300) reflects significant inter-patient variability in response, notes the National Comprehensive Cancer Network 1

Avoiding Common Pitfalls

  • Do not use standard oral-to-IV conversion ratios (typically 3:1), as this patient was receiving intrathecal morphine, not oral, cautions Praxis Medical Insights 3
  • Do not assume linear dose equivalence - incomplete cross-tolerance between routes may require dose adjustments, advise Praxis Medical Insights 3 and 4

REFERENCES

1

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

2

Hydromorphone Dosing Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Opioid Conversion Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Converting Oral Hydromorphone to Subcutaneous Dosing [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025